Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumabRenaud Heine, Carin A. Uyl‐de Groot, Frederick W. Thielen et al.|PLoS ONE|2024Cited by 6
Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint AnalysisMichiel Zietse, Frederick W. Thielen, Thirza Kooijman et al.|JCO Oncology Practice|2025Cited by 5
Omission of dexamethasone in paclitaxel premedication regimens: protocol of the multicentre, randomised, non-inferiority DEXASTOP trialMichiel Zietse, Roelof W. F. van Leeuwen, Leni van Doorn et al.|BMJ Open|2025Cited by 5
Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC studyMichiel Zietse, Frederick W. Thielen, Jun Hu et al.|The Breast|2025Cited by 3
The administration of immune checkpoint inhibitors via an elastomeric pump versus conventional intravenous infusion: an economic perspectiveMichiel Zietse, Carin A. Uyl‐de Groot, Ruben Malmberg et al.|BMC Health Services Research|2024Cited by 1